Like all medicines, this medicine can cause side effects, although not everyone gets them.
The most common side effects with this medicine are dose-dependent and related to its mechanism of action:
Side effectsvery common (can affect more than 1 in 10 people)
Phenomena of visual light (brief moments of increased brightness, caused almost always by sudden changes in light intensity). They can also be described as a halo, flashes of color, image decomposition, or multiple images. These usually appear during the first two months of treatment, after which they may occur repeatedly and resolve during or after treatment.
Side effectscommon (can affect up to 1 in 10 people)
Modification of heart function (symptoms are a slowing of heart rate). This occurs especially in the first 2 to 3 months after starting treatment.
Other side effects have also been reported:
Side effectscommon (can affect up to 1 in 10 people)
Side effectsuncommon (can affect up to 1 in 100 people)
Converted with the trial version of Word Cleaner Server Version, it will only convert 75% of a document.
To remove this message click here to buy the full version now.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging, after CAD. The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of through the drains or in the trash. Deposit the packaging and medicines that you no longer need at the SIGRE collection point of the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines that you no longer need. This will help protect the environment.
Ivabradina Stada 7.5 mg: a film-coated tablet contains 7.5 mg of ivabradina (equivalent to 8.085 mg of ivabradina as a chlorhydrate).
Ivabradina Stada 7.5 mg: film-coated tablets, round, pink, approximately 9.5 mm, marked with “I9VB” on one face and with “7.5” on the other face.
The tablets are presented in PVC/PE/PVDC/Aluminum or Aluminum/Aluminum blister packs of 14, 28, 28 (sample), 56, 98, 100, or 112 film-coated tablets.
Only some sizes of packaging may be commercially available.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona) Spain
Responsible for manufacturing:
Synthon Hispania S.L.
C/Castelló nº1, Pol. Las Salinas
08830 Sant Boi de Llobregat (Barcelona)
Spain
or
Synthon BV
Microweg 22 Nijmegen
6545 CM
Netherlands
or
Synthon s.r.o.
Brnenská 32/cp. 597
678 01 Blansko
Czech Republic
or
STADA Arzneimittel AG
Stadastrasse 2 - 18,
61118 Bad Vilbel
Germany
or
STADA Arzneimittel GmbH
Muthgasse 36/2
1190 Vienna
Austria
or
Clonmel Healthcare Ltd.
Waterford Road
Clonmel, Co. Tipperary
Ireland
or
Centrafarm Services B.V.
Van de Reijtstraat 31-E
4814 NE Breda
Netherlands
This medicine is authorized in the Member States of the European Economic Area with the following names:
ATIvabradin Stada 7.5 mg Filmtabletten
DEIvabradin AL 7.5 mg Filmtabletten
ESIvabradina Stada 7.5 mg comprimidos recubiertos con película EFG
FRIVABRADINE EG 7.5 mg, comprimé pelliculé
ITIVABRADINA EG
NLIvabradine CF 7.5 mg, filmomhulde tabletten
PTIvabradina Ciclum
SIIvabradin Stada 7.5 mg filmsko obložene tablete
SKIvabradín Stada 7.5 mg filmom obalené tablety
Revision date of this leaflet:December 2021
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.